Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Lupin Pharmaceuticals Inc., Baltimore, has initiated a nationwide voluntary recall of 9,210 bottles of its antibiotic Suprax (cefixime) for oral suspension USP 500 mg/5 ml, 10 mL (when reconstituted), precscription only, The Class III recall was...

Novartis detailed plans for its previously announced plans to close its site in Horsham, UK this year following a global review of research locations and a consultation process with associates. The company made the announcement in February....

Mylan Inc. reports that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an abbreviated new drug...

Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA)  at the trade association's annual meeting, succeeding Robert J. Hugin, chairman and CEO of Celgene...

Biogen Idec has appointed Adam M. Koppel, M.D., Ph.D., as senior vice president and chief strategy officer, effective May 15, 2014. Dr. Koppel will be responsible for leading corporate strategy and portfolio management, as well as ensuring...

Teva Pharmaceutical Industries Ltd. announces the approval of the generic equivalent to Lovaza® (omega-3-acid ethyl esters aapsules, USP), in the United States. "Teva believes it is first-to-file and thus far is the only company to receive an...

Mersana Therapeutics, a company specializing antibody drug conjugates (ADCs) and related technology, has entered into a collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company...

Sun Pharmaceutical Industries Ltd. and Ranbaxy Laboratories Ltd  have entered into definitive agreements under which Sun Pharma will acquire 100% of Ranbaxy in an all-stock transaction for $3.2 billion. Under these agreements, Ranbaxy...

Sanofi and its subsidiary Genzyme report that following discussions with FDA,  the company plans to resubmit in the second quarter its supplemental biologics license application seeking approval of Lemtrada (alemtuzumab) for the treatment...